Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070394 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)
A Phase 4 study of Attention Deficit Hyperactivity Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01070394 is a Phase 4 study of Attention Deficit Hyperactivity Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 40 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01070394, a Phase 4 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effectiveness and length of effect of Vyvanse on lessening Attention-Deficit/Hyperactivity Disorder symptoms in adults. The study will also investigate the safety and tolerability of Vyvanse in adults with ADHD.
Conditions Studied
Interventions
- DRUG LDX Treatment
Study Locations (1)
New York
- NYU School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01070394
The ClinicalTrials.gov registry entry for NCT01070394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (81% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which LDX Treatment is the first listed.
NCT01070394 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01070394 about?
NCT01070394 is a clinical study titled "Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)". The purpose of this study is to examine the effectiveness and length of effect of Vyvanse on lessening Attention-Deficit/Hyperactivity Disorder symptoms in adults. The study will also investigate the safety and tolerability of Vyvanse in adults with ADHD.
What is the current status of trial NCT01070394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2010-02. Estimated completion is 2012-07.
What conditions does trial NCT01070394 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT01070394?
The interventions under investigation include: LDX Treatment (DRUG).
Who is sponsoring clinical trial NCT01070394?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01070394 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
R61/33 - VR Study Phase 4
RECRUITING · Phase 4
-
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
RECRUITING · Phase 4
-
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
RECRUITING · Phase 4
-
Stimulant Effects on Disruptive Behavior
RECRUITING · Phase 4
-
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.